A Balancing Act: The Politics of Formularies
This article was originally published in RPM Report
Executive Summary
Medicare Part D relies on formularies to keep costs down and delivery highquality care to beneficiaries. It also revives a long history of political pressure to keep formularies as open as possible.
You may also be interested in...
Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D
The Alzheimer’s Association waged and won a six-month battle to end prior authorization programs for AD medications in three Medicare plans. The skirmish has big implications for future of Medicare formularies— and the balance of power between Big Pharma and managed care.
Part D Pricing and Subpoena Power: What the November Elections Could Mean for Wall Street
The pharmaceutical industry has a lot riding on the mid-term elections: the Democrats only need to take back one chamber of Congress to do damage on Wall Street.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.